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Abstract
Objective—Endothelial nitric oxide synthase (NOS3) activity and cigarette smoking significantly
influence endothelial function. We sought to determine whether cigarette smoking modified the
association between NOS3 polymorphisms and risk of coronary heart disease or stroke.
Methods—All 1085 incident coronary heart disease cases, all 300 incident ischemic stroke cases,
and 1065 reference individuals from the Atherosclerosis Risk in Communities study were genotyped
for the T-786C and E298D polymorphisms in NOS3. Using a case–cohort design, associations
between genotype/haplotype and disease risk were evaluated by multivariable proportional hazards
regression. Multiplicative scale interaction testing evaluated the influence of cigarette smoking
history at baseline on these associations.
Results—In Caucasians, association between E298D genotype and risk of coronary heart disease
was significantly modified by current smoking status (interaction P = 0.013), with the highest risk
observed in smokers carrying the variant D298 allele relative to nonsmokers carrying two E298
alleles (adjusted hazard rate ratio 2.07, 95% confidence interval 1.39−3.07). In African-Americans,
association between T-786C genotype and risk of ischemic stroke was significantly modified by
pack-year smoking history (interaction P = 0.037), with the highest risk observed in ≥ 20 pack-year
smokers carrying the variant C-786 allele relative to < 20 pack-year smokers carrying two T-786
alleles (adjusted hazard rate ratio 4.03, 95% confidence interval 1.54−10.6).
Correspondence and requests for reprints to Dr Darryl C. Zeldin, MD, National Institute of Environmental Health Sciences, 111 T.W.
Alexander Drive, Research Triangle Park, NC 27709, USA. Tel: + 1 919 541 1169; fax: + 1 919 541 4133; e-mail: zeldin@niehs.nih.gov
NIH Public Access
Author Manuscript
Pharmacogenet Genomics. Author manuscript; available in PMC 2007 September 17.
Published in final edited form as:













Conclusions—An interaction between the E298D and T-786C polymorphisms in NOS3, cigarette
smoking, and risk of incident coronary heart disease and ischemic stroke events appears to exist,
suggesting a potential complex interplay between genetic and environmental factors and
cardiovascular disease risk.
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Introduction
Ischemic cardiovascular disease is a major public health problem. It is estimated that 1.2 million
Americans will experience an acute coronary heart disease (CHD) event and 0.7 million will
experience an acute stroke event this year [1]. Endothelial dysfunction is integrally involved
in the pathogenesis of ischemic cardiovascular disease, and has been associated with an
increased risk of myocardial infarction and stroke [2,3].
Nitric oxide is synthesized by endothelial nitric oxide synthase (eNOS, NOS3) in the
vasculature, where it possesses potent vasodilatory [4] and anti-inflammatory [5] effects.
Impairment in eNOS-mediated nitric oxide biosynthesis contributes to endothelial dysfunction
and promotes the development of atherosclerosis [6,7]. Cigarette smoking also contributes to
endothelial dysfunction and atherosclerosis [8], eliciting many of its deleterious endothelial
effects via attenuation of nitric oxide biosynthesis and activity [9,10].
Multiple genetic polymorphisms in NOS3 have been discovered, including the T-786C and
E298D variants that have been associated with reduced nitric oxide biosynthesis [11,12].
Numerous clinical studies evaluating potential associations between NOS3 polymorphisms and
cardiovascular disease risk have reported inconsistent results [13]; however, few have
specifically evaluated the contribution of cigarette smoking, even though smoking may modify
the influence of these polymorphisms on endothelial function [14−17]. The primary aim of our
investigation was to determine whether exposure to cigarette smoke significantly modified the
association between presence of the T-786C or E298D polymorphisms in NOS3 and risk of
incident CHD or ischemic stroke events in individuals enrolled in the biethnic Atherosclerosis
Risk in Communities (ARIC) study.
Methods
Study population
Participants were selected from the ARIC study, a longitudinal, population-based cohort study
of 15 792 men and women aged 45−64 years from four US communities (Forsyth County,
North Carolina; Jackson, Mississippi; Minneapolis, Minnesota; and Washington County,
Maryland) enrolled between 1987 and 1989 [18]. Since enrollment, participants have been
followed prospectively via annual phone interviews, clinic examinations approximately every
3 years through 1998, and ongoing abstraction of hospital and death certificate records. The
study protocol was approved by the Institutional Review Board of each center, and consent
was obtained from each participant.
Ascertainment of incident coronary heart disease and stroke cases
All incident cases that occurred between baseline and December 31, 1998 were evaluated
(median follow-up 9.1 years), excluding participants with a history of CHD or stroke at
baseline. Incident CHD (n = 1085) was defined as (1) definite or probable myocardial infarction
(n = 520), (2) electrocardiographic evidence of silent myocardial infarction (n = 112), (3)
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definite CHD death (n = 110), or (4) coronary revascularization procedure (n = 343). Incident
stroke was defined as a definite or probable ischemic stroke (n = 300).
The ascertainment of cases and criteria for classification have been previously described [19,
20]. All potential events were systematically reviewed and adjudicated by the ARIC Morbidity
and Mortality Classification Committee [18−20]. Hospitalized myocardial infarction was
classified as definite or probable on the basis of chest pain symptoms, cardiac enzyme levels,
and electrocardiographic changes. Definite CHD death was classified on the basis of chest pain
symptoms, underlying cause of death, hospitalization records, and medical history. Coronary
revascularization procedures included coronary artery bypass grafting and percutaneous
coronary intervention. Using the National Survey of Stroke criteria [21], a stroke event was
classified as definite or probable if there was (1) rapid onset of neurological symptoms that
lasted > 24 h or led to death within 24 h, (2) no evidence of pathology that could have mimicked
stroke, and (3) one major (e.g. aphasia or hemiparesis) or two minor (e.g. diplopia or dysarthria)
neurological deficits. Qualifying cases were further classified as ischemic (thrombotic brain
infarction, cardioembolic stroke) or hemorrhagic (subarachnoid hemorrhage, intracerebral
hemorrhage) on the basis of neuroimaging studies and autopsy, when available [20].
Baseline measurements
Detailed demographic, clinical, and biochemical data were obtained from each participant at
baseline. Race was self-reported. Prevalent CHD and stroke were defined as history of a
physician-diagnosed event. Hypertension was defined as systolic blood pressure ≥ 140 mmHg,
diastolic blood pressure ≥ 90 mmHg, or current antihypertensive medication use. Diabetes was
defined as fasting blood glucose ≥ 7.0 mmol/l, nonfasting blood glucose ≥ 11.1 mmol/l,
physician diagnosis, or pharmacologic treatment. Detailed information on cigarette smoking
was obtained through an interview-administered questionnaire, and was defined by current
smoking status (yes/no) and pack-year smoking history ( ≥ 20 or < 20 pack-years).
Cohort random sample
A random sample of all ARIC participants without the history of CHD or stroke at baseline
was assembled to serve as the reference group for the case–cohort comparisons [n = 1065; 85
(57 Caucasians, 28 African-Americans) and 29 (12 Caucasians, 17 African-Americans) of
which are also incident CHD and stroke cases, respectively]. Sampling of the cohort was
stratified on age ( ≥ 55 or < 55 years), sex, and race (Caucasian or African-American). Sampling
proportions varied across each stratum.
Genotyping
Genomic DNA from all incident CHD and ischemic stroke cases and the cohort random sample
was genotyped for the T > C polymorphism at nucleotide position −786 in the proximal
promoter (T-786C) and the G > T polymorphism at nucleotide position 5246 in exon 7
(E298D) of NOS3, using multiplex matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry methods, as described [22]. Briefly, targeted sequences were amplified via
polymerase chain reaction using specific forward (T-786C: 5′-
ACGTTGGATGACTGTAGTTTCCCTAGTCCC-3′; E298D: 5′-
ACGTTGGATGACCTCAAGGACCAGCTCGG-3′) and reverse (T-786C: 5′-
ACGTTGGATGAGGTCAGCAGAGAGACTAGG-3′; E298D: 5′-
ACGTTGGATGAAACGGTCG CTTCGACGTGC-3′) primers for each polymorphism,
followed by extension reactions utilizing specific oligonucleotide primers that annealed
immediately upstream of each polymorphic site and extended the amplification product by a
single base pair in the forward direction (T-786C: 5′-CATCAAGCTCTTCCCTGGC-3′;
E298D: 5′-GCTGCAGGCCCCAGATGA-3′). The mass of the extension reaction products
was determined and translated into genotype using the MassARRAY RT software (Sequenom
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Inc., San Diego, California, USA). Blind replicates were included for quality control. Missing
genotypes were present in < 5% of individuals.
Data analysis
Inverse sampling fractions from each stratum were used as weights in variance estimation of
adjusted covariate means and proportions by linear and logistic regression, respectively. Cohort
random sample allele frequencies were evaluated for deviation from Hardy–Weinberg
equilibrium, and pairwise linkage disequilibrium statistics were calculated (Haploview 3.2;
Broad Institute of Harvard and MIT Cambridge, Massachusetts, USA) [23]. Hazard rate ratios
(HRRs) and 95% confidence intervals (CIs) for the development of incident CHD or ischemic
stroke in relation to genotype were calculated by weighted proportional hazards regression,
using Barlow’s method to account for the stratified random sampling and case–cohort design
[24]. Model 1 included age, sex, and study center as covariates. Model 2 also included
significant clinical covariates, which were current smoking status, diabetes, hypertension,
high-density lipoprotein cholesterol, total cholesterol, and body mass index for the CHD end
point, and current smoking status, diabetes, and hypertension for the stroke end point.
Assuming an autosomal dominant mode of inheritance, individuals with one or two variant
alleles were combined for comparison with wild-type individuals. All analyses were completed
separately in Caucasians and African-Americans. Assuming a case–control design and type I
error α = 0.05, we had approximately 99 and 90% power for the CHD end point and 90 and
80% power for the stroke end point to detect an odds ratio of 2.0 in Caucasians and African-
Americans, respectively.
Haplotypes and their frequencies were estimated using the phase reconstruction method
(PHASE 2.1), which assigned the most probable haplotype pair to each individual [25], and
compared across case status by χ2. Associations between haplotype (0 or 1) and risk of CHD
or stroke were evaluated using Barlow’s method [24], by simultaneously modeling each
haplotype relative to the most common haplotype using the model 2 covariate adjustment
strategy.
Gene–environment interaction testing was completed on a multiplicative scale between
genotype and current smoking status (yes/no) or pack-year smoking history (≥ 20 or < 20 pack-
years) at baseline using a Wald χ2 test for significance of the estimated β-coefficient for the
interaction term [26]. Haplotype–smoking interaction testing was also completed in Caucasians
for the reconstructed haplotype containing both the variant C-786 and D298 alleles; however,
this was not completed in African-Americans because of sample size limitations. As interaction
hypothesis testing on a multiplicative scale is underpowered, the critical value for statistical
significance was set to α = 0.15, two-sided [27]. To minimize the impact of the multiple
statistical tests conducted in our analysis, we estimated the false discovery rate (FDR) q-value
for each interaction test separately for the CHD and stroke end points (QVALUE). The FDR
q-value is defined as the proportion of statistical tests deemed significant that are actually false-
positives [28]. Stratified weighted proportional hazards regression was also completed
according to baseline current smoking status or pack-year smoking history using the model 2




Significant baseline differences in various risk factors were observed between CHD and stroke
cases and noncases included in the cohort random sample (Table 1). Incident CHD and stroke
cases were significantly older and more likely to be men, smokers, diabetic, hypertensive and
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have abnormal fasting lipid panels compared with noncases. Stroke cases were also more likely
to be African-Americans. In the cohort random sample, 71.5% of current smokers at baseline
also had a ≥ 20 pack-year history.
NOS3 genotype
In the cohort random sample, the T-786C (0.371 versus 0.151) and E298D (0.330 versus 0.112)
minor allele frequencies were significantly different in Caucasians and African-Americans,
respectively (P < 0.001). Minimal evidence of pairwise linkage disequilibrium was observed
between these polymorphisms in both Caucasians (D′ = 0.47, r2 = 0.19) and African-Americans
(D′ = 0.41, r2 = 0.12). The allelic distribution of each polymorphism was in Hardy–Weinberg
equilibrium (P > 0.05).
E298D polymorphism
The variant D298 allele was not significantly associated with CHD or ischemic stroke incidence
in either Caucasians or African-Americans (Tables 2 and 3), nor were these relationships
modified by sex. In Caucasians, the relationship between E298D genotype and CHD risk was,
however, significantly modified by baseline current smoking status (interaction P = 0.013, q
= 0.078) and tended to be modified by pack-year smoking history (interaction P = 0.126, q =
0.247), with the highest risk of CHD observed in smokers carrying the variant D298 allele
(Table 4). In the stratified analysis, current smokers with the variant D298 allele were at
significantly greater risk of CHD than smokers with two E298 alleles (HRR 1.84, 95% CI 1.10
−3.09, P = 0.021); however, no association between the variant D298 allele and CHD risk was
observed in nonsmokers (HRR 0.81, 95% CI 0.59−1.10, P = 0.168). Current smoking status
(interaction P = 0.762) and pack-year history (interaction P = 0.641) did not modify the
relationship between E298D genotype and CHD risk in African-Americans (Table 4).
Moreover, neither cigarette smoking exposure estimate modified the relationship between
E298D genotype and risk of ischemic stroke.
T-786C polymorphism
In Caucasians, the variant C-786 allele tended to be more common in CHD cases compared
with noncases (62.7 versus 57.7%, P = 0.079) (Table 2), and was associated with a trend toward
greater CHD risk relative to T-786 homozygotes (HRR 1.24, 95% CI 0.96−1.62, P = 0.106)
(Table 3); although, this did not attain statistical significance. Pack-year smoking history
appeared to modify this association, such that in the stratified analysis ≥ 20 pack-year smokers
carrying the variant C-786 allele were at significantly greater risk of CHD relative to ≥ 20 pack-
year smokers with two T-786 alleles (HRR 1.52, 95% CI 1.01−2.27, P = 0.042). No association
was observed between the variant C-786 allele and CHD risk in < 20 pack-year smokers (HRR
1.06, 95% CI 0.75− 1.51, P = 0.731). In African-Americans, no association between the variant
C-786 allele and risk of CHD was observed (P = 0.421) (Table 3); however, this relationship
tended to be modified by current smoking status (interaction P = 0.142, q = 0.444) (Table 5).
In African-Americans, the variant C-786 allele tended to be more common in incident stroke
cases compared with noncases (39.5 versus 30.3%, P = 0.099) (Table 2), and was associated
with a trend toward greater risk of stroke relative to T-786 homozygotes (HRR 1.63, 95% CI
0.93− 2.88, P = 0.090) (Table 3); although this did not attain statistical significance. This
relationship was not modified by sex. Cigarette smoking exposure, however, significantly
modified this association (interaction P = 0.037, q = 0.148), such that the greatest risk of
ischemic stroke was observed in ≥ 20 pack-year smokers carrying the variant C-786 allele
(Table 5). In ≥ 20 pack-year smokers, stratified analysis demonstrated that the C-786 allele
was more common in stroke cases compared with noncases (41.9 versus 23.4%, P = 0.083),
and was associated with significantly higher risk of stroke relative to ≥ 20 pack-year smokers
with two T-786 alleles (HRR 4.23, 95% CI 1.34−13.4, P = 0.014). No relationship between
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the variant C-786 allele and risk of stroke was observed in < 20 pack-year smokers (HRR 1.08,
95% CI 0.56−2.10, P = 0.813). A similar association was also observed in current smokers
carrying the variant C-786 allele (HRR 2.65, 95% CI 0.99−7.1, P = 0.052), but not nonsmokers
(HRR 1.16, 95% CI 0.55−2.46, P = 0.694). In Caucasians, the variant C-786 allele was not
significantly associated with the risk of ischemic stroke (P = 0.665) (Table 3), nor was this
relationship modified by current smoking status (interaction P = 0.892) or pack-year history
(interaction P = 0.488) (Table 5).
NOS3 haplotypes
Four potential haplotypes were reconstructed, and in Caucasians only haplotype CG (uniquely
tagged by the variant C-786 allele) was significantly more frequent in CHD cases compared
with noncases (16.1 versus 13.1%, P = 0.034) (Table 6) and was associated with a trend toward
greater CHD risk relative to the most common haplotype TG (HRR 1.34, 95% CI 0.97−1.85,
P = 0.072); although this did not attain statistical significance. No significant differences in
haplotype copy frequency were observed across CHD case status in African-Americans, or
across stroke case status in Caucasians and African-Americans (Table 6).
Haplotype CT (uniquely tagged by both the variant C-786 and D298 alleles) was not
significantly associated with risk of CHD relative to haplotype TG (HRR 1.16, 95% CI 0.88
−1.53, P = 0.296). Although no statistically significant interaction between haplotype CT and
either current smoking status (interaction P = 0.179) or pack-year history (interaction P =
0.206) was observed, smokers carrying at least one copy of haplotype CT appeared to
demonstrate higher risk of CHD than nonsmokers without this haplotype (Table 7). In the
stratified analysis, ≥ 20 pack-year smokers carrying haplotype CT were at significantly higher
risk of developing CHD relative to ≥ 20 pack-year smokers with two haplotype TG copies
(HRR 1.55, 95% CI 1.02−2.36, P = 0.041). No association between haplotype CT and CHD
risk was, however, observed in < 20 pack-year smokers (HRR 0.91, 95% CI 0.62−1.33, P =
0.469). A similar but nonsignificant association was also observed in current smokers carrying
haplotype CT (HRR 1.73, 95% CI 0.99−3.02, P = 0.054), but not nonsmokers (HRR 1.01, 95%
CI 0.72−1.42, P = 0.937).
Haplotype CT was not significantly associated with risk of ischemic stroke relative to haplotype
TG (HRR 1.03, 95% CI 0.67−1.58, P = 0.642). Moreover, no significant interaction between
haplotype CT and either current cigarette smoking status (interaction P = 0.309) or pack-year
history (interaction P = 0.610) was observed (Table 7). In the stratified analysis, statistically
significant associations were not observed between haplotype CT and risk of ischemic stroke
in either current smokers (HRR 2.09, 95% CI 0.76−5.77, P = 0.156) or nonsmokers (HRR 0.85,
95% CI 0.52−1.41, P = 0.536) relative to haplotype TG.
Discussion
Our analysis demonstrated no statistically significant associations between the variant C-786
or D298 alleles and risk of either incident CHD or ischemic stroke in Caucasians and African-
Americans enrolled in the ARIC study; although a trend towards higher risk was observed with
the variant C-786 allele for CHD in Caucasians and stroke in African-Americans. Importantly,
our analysis identified a potential interaction between genetic variation in NOS3, cigarette
smoking history, and risk of incident CHD and ischemic stroke events in these individuals.
Specifically, the variant C-786 and D298 alleles appeared to be associated with significantly
higher risk of developing CHD or ischemic stroke in current cigarette smokers and/or those
with a ≥ 20 pack-year history at baseline, whereas these variant alleles were not significantly
associated with disease risk in the absence of the smoking exposure. This interaction was
particularly evident with E298D genotype and CHD risk in Caucasians, and T-786C genotype
and ischemic stroke risk in African-Americans.
Lee et al. Page 6













The role of endothelial dysfunction in the pathogenesis of cardiovascular disease has become
increasingly appreciated. Endothelial dysfunction is typically manifested by impairment in
endothelial-dependent vasodilation, and is associated with increased risk of myocardial
infarction and stroke [2,3]. The vasodilatory, anti-inflammatory, and anti-proliferative
properties of nitric oxide are vital mediators of this process, such that impairment in nitric oxide
biosynthesis and/or activity elicits a substantial worsening of endothelial function and promotes
the development of atherosclerosis [4−7]. Cigarette smoking also contributes significantly to
endothelial dysfunction and atherosclerosis [8], in part through its reduction of eNOS-mediated
nitric oxide biosynthesis via enhanced oxidative stress and eNOS uncoupling [9,10].
Numerous investigations have evaluated associations between NOS3 polymorphisms and
cardiovascular disease. Most have focused on the T-786C and E298D polymorphisms owing
to associations between the variant alleles and reduced nitric oxide biosynthesis [11,12];
however, results have been inconsistent [13]. Importantly, few investigations have evaluated
incident clinical events. Moreover, few have considered the potential influence of cigarette
smoking despite their potential synergistic contribution to worsening endothelial function. For
instance, the variant C-786 allele has been significantly associated with risk of coronary spasm
[15] and decreased cerebral blood flow [16] in smokers, but not nonsmokers. The variant
D298 allele has also been associated with significantly lower endothelial-dependent
vasodilation in smokers, with no significant effect in nonsmokers [17]. Interestingly, the
D298 allele did not influence endothelial-dependent vasodilation in healthy volunteers despite
being associated with reduced systemic nitric oxide levels [29]. These data suggest that
presence of established underlying endothelial dysfunction, as observed in cigarette smokers,
may be necessary for these polymorphisms to significantly attenuate endothelial function and
predispose patients to increased cardiovascular risk. Our findings demonstrating a potential
interaction between the T-786C and E298D polymorphisms, cigarette smoking, and risk of
CHD and stroke events are consistent with this hypothesis.
We observed that associations between the variant D298 and C-786 alleles and CHD incidence
may be significantly modified by exposure to cigarette smoke, such that smokers carrying these
variant alleles were at significantly higher risk of developing CHD compared with nonsmokers
without these variants. Smokers carrying the reconstructed haplotype containing both variant
alleles also appeared to be at greater risk of CHD. Moreover, pack-year history significantly
modified the association between the C-786 allele and ischemic stroke risk in African-
Americans. Collectively, we believe that these data suggest potential existence of a complex
interplay between NOS3 polymorphisms, cigarette smoking exposure, endothelial function,
and cardiovascular disease risk.
Although our study evaluated rigorously ascertained incident events, we are unable to elucidate
mechanisms underlying the observed statistical interactions. We also cannot rule out that the
T-786C and E298D polymorphisms are simply markers in linkage disequilibrium with the true
causative loci. We confirmed that these polymorphisms are, however, not in significant linkage
disequilibrium with each other [13]. A previous epidemiological study reported a significant
interaction between the NOS3 27-base pair repeat polymorphism in intron 4, smoking history,
and risk of angiographically documented CHD [30]. Although we did not evaluate this
polymorphism in our population, previous studies have demonstrated that it is not in significant
linkage disequilibrium with either the E298D or T-786C polymorphisms [13]. Our analysis
also identified a potential haplotype–smoking interaction. As haplotypes are inferred, some
uncertainty exists in the haplotype assigned to each individual. Only two polymorphisms were,
however, included in haplotype reconstruction, posterior haplotype probabilities exceeded 0.83
in all individuals (approximately 75% had a probability of 1.0), and similar haplotype
distributions were observed using the expectation-maximization algorithm [23].
Unfortunately, validation of reported smoking status via biomarkers of tobacco exposure, such
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as urinary cotinine, was not completed in the ARIC study; however, misclassification of
smoking status was expected to be minor and more likely to involve a smoker who failed to
report cigarette consumption in small amounts. Moreover, previous ARIC analyses evaluating
smoking and risk of cardiovascular disease outcomes have been consistent with other
populations [31]. Thus, it is unlikely that misclassification bias, if present, would have a
detectable impact on our estimates.
We acknowledge it is difficult to gauge the statistical significance of these findings considering
the number of comparisons completed in our analysis, and recognize the undesirable
consequences of reporting false-positive findings. Moreover, some of our reported HRRs were
imprecise because of small sample sizes and limited power, particularly in our African-
American and stroke subsets. Even though statistical significance was, however, not
demonstrated with every comparison, we believe our evaluation of two functionally relevant
polymorphisms (T-786C and E298D), two measures of cigarette smoking exposure (current
smoking status and pack-year history), and two incident cardiovascular disease end points
(CHD and ischemic stroke) in Caucasian and African-American individuals enrolled in the
rigorously characterized ARIC study cohort provided a conservative mechanism to
characterize this potential gene–environment interaction at the population level. Overall, we
believe that the internal consistency of our results argue in favor of their validity, albeit at the
cost of an increased number of statistical comparisons. In order to minimize the impact of the
multiple tests completed in our analysis, we also assessed the FDR of our interaction test results.
The estimated q-values for the interactions observed with E298D genotype and CHD risk in
Caucasians (q = 0.078) and T-786C genotype and ischemic stroke risk in African-Americans
(q = 0.148) enhance our confidence in the conclusions drawn from these findings. Moreover,
previous studies have demonstrated that the T-786C and E298D polymorphisms are
particularly associated with endothelial dysfunction in cigarette smokers [15−17], suggesting
that existence of a causal interaction between genetic variation in NOS3 and smoking in the
pathogenesis of CHD and stroke is biologically plausible. Our observation of significant gene–
smoking interactions in the absence of significant genotype–disease associations independent
of the interaction (i.e. main effects), however, suggests that these findings should be interpreted
with caution. Future studies in different populations will undoubtedly be required to validate
our findings and improve our understanding of the complex relationship between NOS3,
cigarette smoking, and ischemic cardiovascular disease.
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Table 1
Baseline characteristics by incident case status
Characteristicsa CRS CHD casesb Stroke casesc
N 1065 1085 300
Sex (%male) 41.4 67.4 53.0
Race (%African-American) 27.2 23.4 45.0
Age (years) 53.8 ± 0.10 55.8 ± 0.17 56.7 ± 0.32
Current smoker (%yes) 24.8 36.1 36.8
Pack-years ≥ 20 (%yes) 29.0 48.6 41.4
Diabetes (%) 11.1 25.1 34.6
Hypertension (%) 29.8 49.4 66.0
SBP (mmHg) 120.4 ± 0.58 128.3 ± 0.63 134.8 ± 1.30
DBP (mmHg) 73.3 ± 0.37 76.2 ± 0.38 79.4 ± 0.81
BMI (kg/m2) 27.7 ± 0.20 28.3 ± 0.15 29.0 ± 0.31
HDL cholesterol (mmol/l) 1.38 ± 0.02 1.12 ± 0.01 1.25 ± 0.02
LDL cholesterol (mmol/l) 3.46 ± 0.03 3.92 ± 0.03 3.75 ± 0.07
Total cholesterol (mmol/l) 5.48 ± 0.03 5.86 ± 0.03 5.76 ± 0.08
Triglycerides (mmol/l) 1.41 ± 0.03 1.87 ± 0.04 1.73 ± 0.07
CRS, cohort random sample; Pack-years, (cigarettes smoked per day/20) × (years smoked); SBP, systolic blood pressure; DBP, diastolic blood pressure;
BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CHD, coronary heart disease.
a
Characteristics weighted according to the sampling fraction. Data presented as mean ± standard error of the mean.
b
P < 0.05 for comparison of CHD cases to 980 non-cases in the CRS for all characteristics.
c
P < 0.05 for comparison of stroke cases to 1036 non-cases in the CRS for all characteristics.
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Table 7
NOS3 haplotype by smoking interaction and risk of incident CHD and stroke in Caucasiansa,b
Smoking exposure Haplotype Interactionc
CHDd Non-CT n = 430/350 CT n = 305/256
Current smoker
 No 1 (referent) 1.00 (0.74−1.35) 1.50 (0.83−2.70)
 Yes 1.46 (1.00−2.13) 2.18 (1.40−3.38) P=0.179
Pack-years
 < 20 years 1 (referent) 0.95 (0.68−1.33) 1.39 (0.84−2.30)
 ≥ 20 years 1.32 (0.93−1.87) 1.74 (1.21−2.51) P=0.206
Strokee Non-CT n = 84/374 CT n = 58/276
Current smoker
 No 1 (referent) 0.87 (0.53−1.45) 1.59 (0.65−3.86)
 Yes 1.67 (0.92−3.04) 2.32 (1.18−4.51) P=0.309
Pack-years
 < 20 years 1 (referent) 0.92 (0.52−1.63) 1.24 (0.54−2.80)
 ≥ 20 years 1.70 (0.98−2.94) 1.93 (0.99−3.74) P=0.610
CHD, coronary heart disease; HRR, hazard rate ratio; CI, confidence interval.
a
Number of cases/noncases in each haplotype cell.
b
Data presented as HRR (95% CI).
c
Multiplicative haplotype by smoking interaction term HRR (95% CI), and P-value.
d
Adjusted for age, sex, study center, diabetes, hypertension, HDL cholesterol, total cholesterol, and body mass index.
e
Adjusted for age, sex, study center, diabetes, and hypertension.
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